The strong numeric efficacy trend, though not yet statistically significant, is a meaningful catalyst for this small-cap biotech. Monitor for final Part A readout and Part B initiation.
Price Chart
Executive Summary
Moleculin Biotech announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML. Both Annamycin dose arms showed complete remission (CR) rates of 43% and 36% versus 12% for the control arm, and composite complete remission (CRc) rates of 50% and 57% versus 29%, though statistical significance was not reached at this interim analysis. The Independent Data Monitoring Committee unanimously recommended continuing the trial as planned.
Key Facts
- CR rates: Annamycin 190 mg/m² + HiDAC 43%, Annamycin 230 mg/m² + HiDAC 36%, control (HiDAC) 12% (n=45, full ITT, no exclusions).
- CRc rates: 50%, 57%, and 29% respectively.
- iDMC found no statistical significance but strong numeric trend favoring Annamycin; recommended continuing trial.
- Trial remains fully powered (80%) for final analysis of ~282 subjects; statistical significance not expected at this interim per O'Brien-Fleming design.
- Enrollment in Part A: 67 of 90 subjects (74%) enrolled; Part A continues toward optimal dose selection.
- Patient population: 75.6% over 60 years, 55.6% prior 7+3, 31.1% prior venetoclax.
Financial Impact
No financial data provided; positive clinical data could enhance pipeline value and financing prospects for Moleculin ($14M market cap).
Risk Factors
- Small sample size (n=45) and lack of statistical significance at this interim analysis.
- Results may not be confirmed in the full study population.
- Company requires additional financing to complete the trial; no committed funding disclosed.
- Competitive landscape for R/R AML therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (MBRX) — Batch item 1 | 0001437749-26-022088 |
| Exhibit: ex_983000.htm | 0001437749-26-022087 |
| Document: 0001437749-26-022088-index-headers.html | 0001437749-26-022088 |
| Document: 0001437749-26-022088-index.html | 0001437749-26-022088 |
| Document: 0001437749-26-022088.txt | 0001437749-26-022088 |
| 8-K Filing (MBRX) — Batch item 6 | 0001437749-26-022087 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers